AZD-9291 | Osimertinib | Mereletinib | CAS 1421373-65-0

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
250 mg	In-stock	$260.00	Visible after login	- +
1 g	In-stock	$650.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

250 mg

In-stock

$260.00

Visible after login

- +

1 g

In-stock

$650.00

Visible after login

- +

Product Overview

Product Name	Osimertinib \| Mereletinib \| AZD-9291
CAS	1421373-65-0
Formula	C28H33N7O2
MW	499.62
Appearance	Off-white powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

Osimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. Osimertinib was approved in Nov. 2015 by FDA.

Related literature

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

PMID: 24893891 PMCID: PMC4315625 DOI: 10.1158/2159-8290.CD-14-0337

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.

PMID: 29467275 DOI: 10.1158/1535-7163.MCT-17-1033